Prostamax

Preclinical only Hormonal Health 2 sources

Prostamax is a synthetic peptide bioregulator developed to target prostate tissue and function. Research suggests it may influence chromatin structural dynamics, reduce inflammation in prostate tissue models, and potentially normalize androgen receptor expression.

01Dosing reference

Amount

1-2 mg per day (from reconstituted 10-20 mg vials)

Frequency

Once daily via SubQ injection

Cycle

10-20 days, repeated every 3-6 months

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Chromatin Interaction

Binds to DNA and histones in prostate cells.

Epigenetic Regulation

Induces alterations in chromatin architecture, potentially activating previously repressed genes.

Anti-inflammatory Action

Reduces inflammatory cytokine gene transcription, alleviating swelling and cellular infiltration in prostate tissue.

03Human evidence

Limited to anecdotal or early Eastern European clinical observations.

While widely used as a bioregulator in Russia, large-scale, peer-reviewed Western clinical trials are lacking.

Potential symptom relief in prostatitis.

Some early reports suggest improvements in urinary symptoms and reduced prostate inflammation, though robust placebo-controlled data is needed.

04Preclinical evidence

Reduction of chronic aseptic prostatitis signs.

In animal models, Prostamax reduced swelling, vessel hyperemia, and lymphoid infiltration.

Prevention of sclerosal processes.

Animal studies demonstrated that Prostamax blocked the development of sclerosal processes in prostate tissue.

05What is known vs. unknown

Reasonably established

Prostamax is a synthetic peptide bioregulator based on the research of Vladimir Khavinson.
It is designed to specifically target and support prostate tissue health.
Research indicates it may work via epigenetic mechanisms, altering chromatin structure to regulate gene expression.
Preclinical models show significant anti-inflammatory effects in prostate tissue.

Unknowns & limits

Lack of large-scale, randomized, double-blind clinical trials in humans.
Long-term safety and efficacy data are not well established in Western medical literature.
Exact binding sites and full downstream epigenetic effects remain partially understood.

06Safety & regulatory context

Regulatory statusProstamax is not approved by the FDA for the treatment, prevention, or diagnosis of any condition, including prostatitis, BPH, or prostate cancer. It is currently classified as a research chemical. While peptide bioregulators are generally considered to have a favorable safety profile in early studies, potential side effects, long-term risks, and contraindications are not fully documented. It should not be used as a replacement for standard medical therapies.

07Compared with Libidon

Prostamax vs. Libidon

Key difference

Libidon is a natural (animal-derived) prostate peptide bioregulator, whereas Prostamax is a synthesized peptide designed to mimic similar effects.

When researchers discuss each

Researchers discuss Libidon when focusing on natural glandular extracts, and Prostamax when studying targeted, synthetic epigenetic regulation of prostate tissue.

08Glossary

Peptide Bioregulator

A short chain of amino acids that interacts with DNA to regulate gene expression and restore cellular function.

Chromatin

A complex of DNA and proteins that forms chromosomes within the nucleus of eukaryotic cells.

Prostatitis

Swelling and inflammation of the prostate gland.

09Knowledge check

Q1What is the primary proposed mechanism of action for Prostamax?

Q2In preclinical models of prostatitis, what effect did Prostamax demonstrate?

Q3Which statement best reflects the current strength and limitations of the evidence supporting Prostamax for human use?

Q4According to the dossier, how do researchers generally distinguish when to study Prostamax versus Libidon?

Q5Which statement most accurately summarizes Prostamax's regulatory and safety context as described in the dossier?

10Sources

More in Hormonal Health

See all

Kisspeptin-10

Hormonal Health

Human clinical

Kisspeptin-10 is a potent neuropeptide that acts as an upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Research shows it stimulates the release of gonadotropin-releasing hormone (GnRH), subsequently increasing luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels. It is heavily studied for its potential in treating infertility, hypogonadism, and reproductive disorders.

100-300 mcg per dose

Gonadorelin

Hormonal Health

FDA-approved context

Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH). It stimulates the anterior pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate the gonads to produce testosterone and sperm in males, and estrogen and eggs in females.

100-200 mcg per dose

hCG (Human Chorionic Gonadotropin)

Hormonal Health

FDA-approved context

hCG is a hormone naturally produced during pregnancy that mimics luteinizing hormone (LH) in the body. In research and clinical settings, it is widely used to stimulate testosterone production, preserve fertility, and treat hypogonadism in men, as well as to induce ovulation in women.

250-500 IU

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.